You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

How type 2 cytokines can amplify inflammatory response in CSU

Dr. Thomos Casale explores the role of Th2 inflammation in CSU, highlighting the impact of IgE autoantibodies and the need for targeted therapies against Th2 cytokines.

Thomas Casale
MD
Thomas Casale

Learning objectives

  • Explain the role of IgE autoantibodies and their interaction with mast cells in the pathophysiology of CSU.
  • Understand the significance of targeting Th2 cytokines for developing targeted therapies in CSU.
Tags
expert insightstype 2 inflammationcytokinesIL-13IL-4IL-5
MAT-US-2407281 V1.0 Exp Date: 06/18/2026

About this expert

Allergy/Immunology

Thomas Casale

MD

Professor of Medicine and Pediatrics; Chief of Clinical and Translational Research, University of South Florida, Tampa, United States

See author’s profile
Thomas Casale

Related resources

Barrier Disruption in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Barrier Disruption in Atopic Dermatitis and Food Allergy

Type 2 Inflammation in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Clinical Assessment of Prurigo Nodularis
Dermatology
expert video

Clinical Assessment of Prurigo Nodularis

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU
Dermatology
expert video

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU

An Overview of Prurigo Nodularis
Dermatology
expert video

An Overview of Prurigo Nodularis

Atopic Dermatitis as a Risk Factor for Food Allergy
Type 2 Inflammation
expert video

Atopic Dermatitis as a Risk Factor for Food Allergy

EAACI 2022 | Unmet Needs in the Diagnosis and Management of Chronic Urticaria
Dermatology
expert video

EAACI 2022 | Unmet Needs in the Diagnosis and Management of Chronic Urticaria

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation
Dermatology
expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

The Journey to Diagnosis: Considerations For AD, PN, and CSU
Dermatology
expert video

The Journey to Diagnosis: Considerations For AD, PN, and CSU

Pathophysiology of Prurigo Nodularis
Dermatology
expert video

Pathophysiology of Prurigo Nodularis

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Dermatology
expert video

Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis
Dermatology
expert video

The Journey of Diagnosis: Disease Burden and Diagnostic Considerations for Atopic Dermatitis and Prurigo Nodularis

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis
Dermatology
expert video

Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis
Dermatology
videoanimation

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.
Dermatology
Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU
Dermatology
Infographic

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD
Dermatology
expert video

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies
Dermatology
expert video

Barrier disruption in AD and the development of environmental and food allergies

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

CSU is Associated With a High Burden and Impact on Quality of Life
Dermatology
expert video

CSU is Associated With a High Burden and Impact on Quality of Life

How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
expert video

How type 2 cytokines can amplify inflammatory response in CSU

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region